China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche

Reuters

10/17

UPDATE 1-China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche

Adds further details from paragraph 2 onwards

Oct 17 (Reuters) - Chinese biotech Hansoh Pharma 3692.HK said on Friday it had signed a licence agreement worth up to $1.45 billion with Roche ROG.S for an investigational treatment of colorectal cancer and other solid tumours.

Hansoh Pharma units Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche an exclusive worldwide licence to develop, manufacture and commercialise the product.

The licence excludes rights in the Chinese Mainland, Hong Kong, Macau and Taiwan.

The licensors will receive an upfront payment of $80 million and be eligible to receive up to $1.45 billion in milestone payments associated with the development, regulatory approval and commercialisation of the product, among others.

(Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber and Subhranshu Sahu)

((Sneha.Kumar@thomsonreuters.com))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2576772937"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576772937\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576772937?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 07:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576772937","market":"us","top_or_hot":-1,"title":"China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 1-China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche</title></head><body><p>Adds further details from paragraph 2 onwards</p><p><span>Oct 17 (Reuters)</span><span> - </span>Chinese biotech Hansoh Pharma <span>3692.HK</span> said on Friday it had signed a licence agreement worth up to $1.45 billion with Roche <span>ROG.S</span> for an investigational treatment of colorectal cancer and other solid tumours.</p><p>Hansoh Pharma units Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche an exclusive worldwide licence to develop, manufacture and commercialise the product.</p><p>The licence excludes rights in the Chinese Mainland, Hong Kong, Macau and Taiwan.</p><p>The licensors will receive an upfront payment of $80 million and be eligible to receive up to $1.45 billion in milestone payments associated with the development, regulatory approval and commercialisation of the product, among others. </p><p> (Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber and Subhranshu Sahu)</p><p> ((Sneha.Kumar@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-17 07:43</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 1-China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche</title></head><body><p>Adds further details from paragraph 2 onwards</p><p><span>Oct 17 (Reuters)</span><span> - </span>Chinese biotech Hansoh Pharma <span>3692.HK</span> said on Friday it had signed a licence agreement worth up to $1.45 billion with Roche <span>ROG.S</span> for an investigational treatment of colorectal cancer and other solid tumours.</p><p>Hansoh Pharma units Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche an exclusive worldwide licence to develop, manufacture and commercialise the product.</p><p>The licence excludes rights in the Chinese Mainland, Hong Kong, Macau and Taiwan.</p><p>The licensors will receive an upfront payment of $80 million and be eligible to receive up to $1.45 billion in milestone payments associated with the development, regulatory approval and commercialisation of the product, among others. </p><p> (Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber and Subhranshu Sahu)</p><p> ((Sneha.Kumar@thomsonreuters.com))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL6N3VX19N:1","article_id":"2576772937","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576772937","pubTimestamp":1760658183,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"UPDATE 1-China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with RocheAdds further details from paragraph 2 onwardsOct 17  - Chinese biotech Hansoh Pharma 3692.HK said on Friday it had signed a licence agreement worth up to $1.45 billion with Roche ROG.S for an investigational treatment of colorectal cancer and other solid tumours.Hansoh Pharma units Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche an exclusive worldwide licence to develop, manufacture and commercialise the product.The licence excludes rights in the Chinese Mainland, Hong Kong, Macau and Taiwan.The licensors will receive an upfront payment of $80 million and be eligible to receive up to $1.45 billion in milestone payments associated with the development, regulatory approval and commercialisation of the product, among others.   ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1583":"高瓴概念","BK1589":"北水核心资产","03692":"翰森制药"},"translate_title":"中国豪森与罗氏签署价值14.5亿美元的结直肠癌药物协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"UPDATE 1-China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with RocheAdds further details from paragraph 2 onwardsOct 17 (Reuters) - Chinese biotech Hansoh Pharma 3692.HK said on Friday it had signed a licence agreement worth up to $1.45 billion with Roche ROG.S for an investigational treatment of colorectal cancer and other solid tumours.Hansoh Pharma units Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche an exclusive worldwide licence to develop, manufacture and commercialise the product.The licence excludes rights in the Chinese Mainland, Hong Kong, Macau and Taiwan.The licensors will receive an upfront payment of $80 million and be eligible to receive up to $1.45 billion in milestone payments associated with the development, regulatory approval and commercialisation of the product, among others.  (Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber and Subhranshu Sahu) ((Sneha.Kumar@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}